Despite the clinical success of anti-CD19 chimeric antigen receptor (CAR) T cell therapy in acute lymphocytic leukemia, the role of CD19 in the proliferation of lymphoma cells driven by the My-T-BCR complex has not been fully elucidated. This evidence concerns the gene CD19 and lymphoma.